Curium Eyes Lantheus Acquisition in Multi-Billion Dollar Deal

Curium, a firm supported by Capvest Partners, is reportedly in advanced negotiations to acquire Lantheus Holdings Inc. Sources close to the matter suggest that an announcement regarding this potential acquisition could be made in the coming days.

The proposed terms include an upfront payment of approximately $102 per share. Additionally, Lantheus shareholders could receive a further $12.50 per share as part of an earn-out, contingent on certain performance milestones being met. This structure indicates a strategic approach to integrating Lantheus and realizing its future value.

This development signifies a potentially major consolidation within the radiopharmaceutical industry. Both companies operate in a sector critical for diagnostic and therapeutic applications, making this merger a noteworthy event for the healthcare landscape.